Certara, Inc. (NASDAQ:CERT) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. reduced its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 58.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 730,586 shares of the company's stock after selling 1,014,885 shares during the quarter. Franklin Resources Inc. owned 0.45% of Certara worth $8,212,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CERT. Brown Brothers Harriman & Co. bought a new position in Certara in the third quarter worth approximately $27,292,000. Wasatch Advisors LP lifted its stake in Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock worth $105,577,000 after acquiring an additional 1,651,076 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock worth $45,691,000 after acquiring an additional 1,128,006 shares in the last quarter. Daventry Group LP increased its position in Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company's stock valued at $18,124,000 after purchasing an additional 791,405 shares during the period. Finally, Glenmede Trust Co. NA raised its holdings in shares of Certara by 78.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company's stock valued at $14,123,000 after purchasing an additional 530,598 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company's stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.39% of the company's stock.

Certara Stock Performance

Shares of NASDAQ:CERT traded up $0.03 during trading on Monday, hitting $10.74. 977,234 shares of the stock traded hands, compared to its average volume of 853,243. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average price of $10.81 and a two-hundred day moving average price of $12.39. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -53.70, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 earnings per share. As a group, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

CERT has been the topic of several research reports. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. Barclays decreased their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, November 7th. Finally, UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.